Cargando…

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration

Anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) has been FDA-approved in 2004, and since then has helped tens of thousands of patients worldwide to preserve vision. Still, treatment responses vary widely, emphasizing the need for genetic biomarkers to robustly separate re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strunz, Tobias, Pöllmann, Michael, Gamulescu, Maria-Andreea, Tamm, Svenja, Weber, Bernhard H. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181567/ https://www.ncbi.nlm.nih.gov/pubmed/35682771 http://dx.doi.org/10.3390/ijms23116094

Ejemplares similares

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Epistatic interactions of genetic loci associated with age-related macular degeneration
por: Kiel, Christina, et al.
Publicado: (2021)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Pleiotropic Locus 15q24.1 Reveals a Gender-Specific Association with Neovascular but Not Atrophic Age-Related Macular Degeneration (AMD)
por: Kiel, Christina, et al.
Publicado: (2020)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2016)

Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy
por: Prea, Selwyn M., et al.
Publicado: (2015)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration
por: Mantel, Irmela, et al.
Publicado: (2019)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
por: Cao, Xuan, et al.
Publicado: (2022)

Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration
por: Miyata, Manabu, et al.
Publicado: (2021)

Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment
por: Yeter, D.Y., et al.
Publicado: (2021)

OCT-Derived Radiomic Features Predict Anti–VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
por: Kar, Sudeshna Sil, et al.
Publicado: (2022)

Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
por: Chujo, Shinichiro, et al.
Publicado: (2023)

Decrease in Anti-VEGF Injections After Post-injection Endophthalmitis in Patients With Neovascular Age-Related Macular Degeneration
por: Binczyk, Natalia M., et al.
Publicado: (2023)

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration
por: Balikova, Irina, et al.
Publicado: (2019)

Learning from Fifteen Years of Genome-Wide Association Studies in Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2020)

Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
por: Riaz, Moeen, et al.
Publicado: (2017)

Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes
por: Pedrosa, Ana Catarina, et al.
Publicado: (2017)

A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017)

Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration
por: Eng, Victor A., et al.
Publicado: (2020)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularization Caused by Pathologies Other Than Age-Related Macular Degeneration
por: Ozveren, Mehmet
Publicado: (2020)

Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
por: Zola, Marta, et al.
Publicado: (2020)

Prevalence of Polypoidal Choroidal Vasculopathy in Eyes with Neovascular Age-Related Macular Degeneration Resistant to Intravitreal Anti-VEGF Treatment
por: Menteş, Jale, et al.
Publicado: (2022)

Radiomics-Based Prediction of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment
por: Williamson, Ryan Chace, et al.
Publicado: (2023)

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
por: Barth, T., et al.
Publicado: (2019)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls
por: Türksever, Cengiz, et al.
Publicado: (2023)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
por: Lin, Liang-Wei, et al.
Publicado: (2023)

Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision
por: Frenkel, Ronald E P, et al.
Publicado: (2016)

Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
por: Panos, Georgios D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g0i1phusp8kf6cb9fq7kur0j0r